Articles from Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective menin inhibitor for the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement, to allow for interim analysis. Achieving this milestone will enable SMPA to obtain results of the interim analysis by the end of calendar year 2026. These results will be promptly disclosed, with detailed data to be presented at an upcoming medical congress. If the primary endpoint is met, SMPA would then proceed with preparation for regulatory submission with the aim of obtaining approval in the US and Japan during FY2027.

Sumitomo Pharma America, Inc. (SMPA) today announced clinical data from its ongoing first-in-human Phase 1/2 trial of SMP-3124LP (NCT06526819). SMP-3124LP is a structurally distinct, investigational, selective checkpoint kinase 1 (CHK1) inhibitor delivered via a PEGylated liposome formulation. Designed with the specific goal of treating malignancies characterized by high replication stress, these findings were presented as a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May 15–18 in Washington, D.C. The presentations include a featured subgroup analysis of the phase 3 COURAGE trial evaluating vibegron in older men, along with real-world evidence from the OPTYX study of relugolix in advanced prostate cancer.